Dvago Logo
    location icon

    Dvago Logo

    Delivers in

      location icon


      Viglip-M Tablets 50Mg/500Mg

      Rs. 522.48

      Rs. 550.00



      Viglip-M Tablets Specification

      Requires Prescription (YES/NO)



      Vildagliptin + Metformin HCl

      Used For


      How it works

      The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). Metformin HCl decreases hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis, decrease intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

      Viglip-M Tablets Usage And Safety


      Vildagliptin + Metformin HCl

      Side Effects

      Hypoglycemia, tremor, headache, dizziness & nausea , Fatigue , Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia , Decreased blood glucose, headache, chills, nausea, gastro-esophageal reflux disease , diarrhea & flatulence.

      Drug Interactions

      Thiazides, corticosteroids, thyroid products and sympathomimetics , Furosemide , Nifedipine , Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) , estrogens, oral contraceptives, phenytoin, nicotinic acid , alcohol.


      Vildagliptin + Metformin HCl is indicated for the treatment of patients with Type 2 diabetes mellitus (T2DM). Vildagliptin + Metformin HCl is indicated as an adjunct to diet and exercise to improve glycemic control in patients whose diabetes is not adequately controlled on metformin HCl alone or who are already treated with the combination of vildagliptin and metformin HCl, as separate tablets.

      When not to Use

      Vildagliptin + Metformin HCl combination is contraindicated in: - Patients with known hypersensitivity to vildagliptin or metformin HCl or to any excipient of the product. - Diabetic ketoacidosis or diabetic pre-coma.

      Viglip-M Tablets Precautions


      Vildagliptin + Metformin HCl combination is not substitute for insulin-requiring patients and should not be used in patients with type 1 diabetes.

      Viglip-M Tablets Warnings

      Warning 1

      In diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.

      Warning 2

      Use of vildagliptin has been associated with a risk of developing acute pancreatitis. If pancreatitis is suspected, vildagliptin should be discontinued and if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.

      Warning 3

      Treatment with metformin should be discontinued 48 hours before elective surgery with general anesthesia and should not usually be resumed earlier than 48 hours afterwards.

      Viglip-M Tablets Additional Information

      Pregnancy category

      Always consult your physician before using any medicine.

      Storage (YES/NO)

      Store this medicine at room temperature, away from direct light and heat.

      Related Products

      • medicine

        Product Image